Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA; Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA.
Semin Immunol. 2021 Jan;51:101475. doi: 10.1016/j.smim.2021.101475. Epub 2021 Apr 12.
Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional tools to prevent and treat HIV-1 are therefore necessary. The identification of potent and broadly neutralizing antibodies (bNAbs) against HIV-1 has revolutionized the field and may prove clinically useful. Significant advances have been made in identifying broader and more potent antibodies, characterizing antibodies in preclinical animal models, engineering antibodies to extend half-life and expand breadth and functionality, and evaluating the efficacy of single bNAbs and bNAb combinations in people with and without HIV-1. Here, we review recent progress in developing bNAbs for the prevention and treatment of HIV-1.
尽管我们在预防和治疗 HIV-1 感染方面取得了巨大进展，但 HIV-1 仍然是一种无法治愈的疾病，而且高效的 HIV-1 疫苗尚未问世。因此，需要额外的工具来预防和治疗 HIV-1。针对 HIV-1 的有效且广泛中和的抗体 (bNAb) 的鉴定彻底改变了这一领域，并可能具有临床应用价值。在鉴定更广泛和更有效的抗体、在临床前动物模型中对抗体进行表征、对抗体进行工程改造以延长半衰期并扩大广度和功能，以及评估单 bNAb 和 bNAb 组合在 HIV-1 感染者和未感染者中的疗效方面，已经取得了重大进展。在这里，我们回顾了为预防和治疗 HIV-1 而开发 bNAb 的最新进展。
